Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Sector Gamma AS

Sector Gamma AS boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 132,478 shares of the medical equipment provider’s stock after acquiring an additional 19,000 shares during the period. Zimmer Biomet comprises approximately 2.7% of Sector Gamma AS’s investment portfolio, making the stock its 15th largest position. Sector Gamma AS’s holdings in Zimmer Biomet were worth $11,912,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ZBH. Brighton Jones LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter worth about $204,000. Sivia Capital Partners LLC bought a new stake in shares of Zimmer Biomet in the 2nd quarter worth about $232,000. United Bank increased its position in shares of Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after purchasing an additional 1,202 shares during the last quarter. Finally, Cerity Partners LLC increased its position in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after purchasing an additional 37,116 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Trading Down 1.0%

NYSE ZBH opened at $87.26 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29. The company has a 50-day simple moving average of $87.61 and a 200-day simple moving average of $90.44. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The firm has a market capitalization of $16.88 billion, a PE ratio of 22.67, a price-to-earnings-growth ratio of 2.04 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same period in the previous year, the business posted $1.81 EPS. The company’s quarterly revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is 24.94%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZBH. Citigroup dropped their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Stifel Nicolaus dropped their target price on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Truist Financial reissued a “hold” rating and issued a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. William Blair began coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They issued a “market perform” rating for the company. Finally, Citizens Jmp dropped their target price on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $102.70.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.